Learn about the latest technology for migraine relief with neuromodulation device therapy. Understand potential risks and ...
--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, today announced a $ ...
Biohaven Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases. The compounds are oral ...
An initial clinical trial, published in August in the American Journal of Psychiatry, demonstrated a significant reduction in symptom severity among participants with MDD. Notably, 80% of patients ...